NCT03157128: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 857 taking part
- Started
- 2 May 2017
- Primary completion
- 14 Feb 2025
- Arms
- Phase 1: 20 mg Selpercatinib QD, Phase 1: 20 mg Selpercatinib BID, Phase 1: 40 mg Selpercatinib BID, Phase 1: 60 mg Selpercatinib BID, Phase 1: 160 mg Selpercatinib QD, Phase 1: 80 mg Selpercatinib BID, Phase 1: 120 mg Selpercatinib BID, Phase 1: 160 mg Selpercatinib BID, Phase 1: 200 mg Selpercatinib BID, Phase 1: 240 mg Selpercatinib BID, Phase 2, Cohort 1: RET Fusion Solid Tumor, Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy, Phase 2, Cohort 3: RET Mutant MTC, Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy, Phase 2, Cohort 5: Advanced RET Altered Solid Tumor, Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
- Results
- Posted on the registry
- 2 May 2017: Trial started
- 17 May 2017: Trial registered
- 16 Apr 2026: Trial results posted